Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Interactive Journal Club: Teaching an Old Dog New Tricks.

Rosenthal J, Rosenthal KS.

J Med Educ Curric Dev. 2017 Jul 21;4:2382120517719710. doi: 10.1177/2382120517719710. eCollection 2017 Jan-Dec.

2.

An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis.

Mikecz K, Glant TT, Markovics A, Rosenthal KS, Kurko J, Carambula RE, Cress S, Steiner HL Rd, Zimmerman DH.

Vaccine. 2017 Jul 13;35(32):4048-4056. doi: 10.1016/j.vaccine.2017.05.009. Epub 2017 Jun 3.

3.

LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model.

Rosenthal KS, Stone S, Koski G, Zimmerman DH.

J Immunol Res. 2017;2017:3613505. doi: 10.1155/2017/3613505. Epub 2017 Mar 26.

4.

Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.

Rosenthal KS, Mikecz K, Steiner HL 3rd, Glant TT, Finnegan A, Carambula RE, Zimmerman DH.

Expert Rev Vaccines. 2015 Jun;14(6):891-908. doi: 10.1586/14760584.2015.1026330. Epub 2015 Mar 18. Review.

5.

Concurrent treatment of chronic psoriasis and asthma with ustekinumab.

Amarnani A, Rosenthal KS, Mercado JM, Brodell RT.

J Dermatolog Treat. 2014 Feb;25(1):63-6. doi: 10.3109/09546634.2013.782095. Epub 2013 May 6.

PMID:
23469809
6.

LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases.

Zimmerman DH, Steiner H 3rd, Carmabula R, Talor E, Rosenthal KS.

J Vaccines Vaccin. 2012 Sep 20;3(5). pii: 149.

7.

Extracellular ATP and Toll-like receptor 2 agonists trigger in human monocytes an activation program that favors T helper 17.

Paustian C, Taylor P, Johnson T, Xu M, Ramirez N, Rosenthal KS, Shu S, Cohen PA, Czerniecki BJ, Koski GK.

PLoS One. 2013;8(1):e54804. doi: 10.1371/journal.pone.0054804. Epub 2013 Jan 31.

8.

J-LEAPS peptide and LEAPS dendritic cell vaccines.

Rosenthal KS, Taylor P, Zimmerman DH.

Microb Biotechnol. 2012 Mar;5(2):203-13. doi: 10.1111/j.1751-7915.2011.00278.x. Epub 2011 Sep 6. Review.

9.

J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells.

Taylor PR, Koski GK, Paustian CC, Bailey E, Cohen PA, Moore FB, Zimmerman DH, Rosenthal KS.

Vaccine. 2010 Aug 2;28(34):5533-42. doi: 10.1016/j.vaccine.2010.06.043. Epub 2010 Jun 25.

PMID:
20600501
10.

Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens.

Taylor PR, Paustian CC, Koski GK, Zimmerman DH, Rosenthal KS.

Cell Immunol. 2010;262(1):1-5. doi: 10.1016/j.cellimm.2010.01.003. Epub 2010 Feb 1.

11.

CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model.

Zimmerman DH, Taylor P, Bendele A, Carambula R, Duzant Y, Lowe V, O'Neill SP, Talor E, Rosenthal KS.

Int Immunopharmacol. 2010 Apr;10(4):412-21. doi: 10.1016/j.intimp.2009.12.016. Epub 2010 Jan 13.

PMID:
20074669
12.

A new bioartificial pancreas utilizing amphiphilic membranes for the immunoisolation of porcine islets: a pilot study in the canine.

Grundfest-Broniatowski SF, Tellioglu G, Rosenthal KS, Kang J, Erdodi G, Yalcin B, Cakmak M, Drazba J, Bennett A, Lu L, Kennedy JP.

ASAIO J. 2009 Jul-Aug;55(4):400-5. doi: 10.1097/MAT.0b013e3181a8deba.

PMID:
19506465
13.

HSV-2 ICP34.5 protein modulates herpes simplex virus glycoprotein processing.

Chatterjee S, Wang JW, Cismowski MJ, Bower JR, Rosenthal KS.

Arch Virol. 2009;154(4):661-3. doi: 10.1007/s00705-009-0341-9. Epub 2009 Mar 7.

PMID:
19267180
14.

A novel macroencapsulating immunoisolatory device: the preparation and properties of nanomat-reinforced amphiphilic co-networks deposited on perforated metal scaffold.

Erdodi G, Kang J, Yalcin B, Cakmak M, Rosenthal KS, Grundfest-Broniatowski S, Kennedy JP.

Biomed Microdevices. 2009 Feb;11(1):297-312. doi: 10.1007/s10544-008-9236-x.

PMID:
18987977
15.

Vaccines: all things considered.

Rosenthal KS, Zimmerman DH.

Clin Vaccine Immunol. 2006 Aug;13(8):821-9. Review. No abstract available.

16.

Vaccines-all things considered. Part II. 2-3 December 2004, San Francisco, CA, USA.

Rosenthal KS.

IDrugs. 2005 Feb;8(2):110-1. No abstract available.

PMID:
15696409
17.

Vaccines--all things considered. Part I. 2-3 December 2004, San Francisco, CA, USA.

Rosenthal KS.

IDrugs. 2005 Feb;8(2):107-9. No abstract available.

PMID:
15696408
18.

Immune peptide enhancement of peptide based vaccines.

Rosenthal KS.

Front Biosci. 2005 Jan 1;10:478-82. Print 2005 Jan 1. Review.

PMID:
15574384
19.

Ligand epitope antigen presentation system vaccines against herpes simplex virus.

Goel N, Zimmerman DH, Rosenthal KS.

Front Biosci. 2005 Jan 1;10:966-74. Print 2005 Jan 1. Review.

PMID:
15569635
20.

The L.E.A.P.S. approach to vaccine development.

Zimmerman DH, Rosenthal KS.

Front Biosci. 2005 Jan 1;10:790-8. Print 2005 Jan 1. Review.

PMID:
15569618
21.

CEL-1000--a peptide with adjuvant activity for Th1 immune responses.

Charoenvit Y, Goel N, Whelan M, Rosenthal KS, Zimmerman DH.

Vaccine. 2004 Jun 23;22(19):2368-73.

PMID:
15193396
22.

A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection.

Goel N, Rong Q, Zimmerman D, Rosenthal KS.

Vaccine. 2003 Oct 1;21(27-30):4410-20.

PMID:
14505924
23.

Synthesis, permeability and biocompatibility of tricomponent membranes containing polyethylene glycol, polydimethylsiloxane and polypentamethylcyclopentasiloxane domains.

Kurian P, Kasibhatla B, Daum J, Burns CA, Moosa M, Rosenthal KS, Kennedy JP.

Biomaterials. 2003 Sep;24(20):3493-503.

PMID:
12809778
24.

Characterization and performance of membranes designed for macroencapsulation/implantation of pancreatic islet cells.

Isayeva IS, Kasibhatla BT, Rosenthal KS, Kennedy JP.

Biomaterials. 2003 Sep;24(20):3483-91.

PMID:
12809777
26.

Multiple mechanisms for HSV-1 induction of interferon alpha production by peripheral blood mononuclear cells.

Rong Q, Alexander TS, Koski GK, Rosenthal KS.

Arch Virol. 2003 Feb;148(2):329-44.

PMID:
12556996
27.

A modification of the epidermal scarification model of herpes simplex virus infection to achieve a reproducible and uniform progression of disease.

Goel N, Docherty JJ, Fu MM, Zimmerman DH, Rosenthal KS.

J Virol Methods. 2002 Dec;106(2):153-8.

PMID:
12393145
28.

The ability of an HSV strain to initiate zosteriform spread correlates with its neuroinvasive disease potential.

Goel N, Mao H, Rong Q, Docherty JJ, Zimmerman D, Rosenthal KS.

Arch Virol. 2002 Apr;147(4):763-73.

PMID:
12038686
30.

Changes in BiP (GRP78) levels upon HSV-1 infection are strain dependent.

Mao H, Palmer D, Rosenthal KS.

Virus Res. 2001 Aug;76(2):127-35.

PMID:
11410313
31.

Synthesis of radioactive single-stranded DNA probes using asymmetrical PCR and oligonucleotide random priming.

Mao H, Rosenthal KS.

Biotechniques. 1999 Oct;27(4):674-6, 678. No abstract available.

32.
34.
35.

Inhibition of the G2/M transition of the cell cycle by methyl-2,5-dihydroxycinnamate in human lymphoid cells.

Koch JA, Rosenthal KS, Jamison JM, Summers JL.

Biochem Biophys Res Commun. 1996 Aug 14;225(2):531-6.

PMID:
8753796
37.
38.

Autologous antibody is protective against HSV-1 infection of the immunocompromised mouse.

Alexander TS, Rosenthal KS.

J Lab Clin Med. 1990 Sep;116(3):400-7.

PMID:
2169516
39.

Tromantadine inhibits a late step in herpes simplex virus type 1 replication and syncytium formation.

Ickes DE, Venetta TM, Phonphok Y, Rosenthal KS.

Antiviral Res. 1990 Aug;14(2):75-85.

PMID:
2177318
40.

Mild acidic pH inhibition of the major pathway of herpes simplex virus entry into HEp-2 cells.

Rosenthal KS, Killius J, Hodnichak CM, Venetta TM, Gyurgyik L, Janiga K.

J Gen Virol. 1989 Apr;70 ( Pt 4):857-67.

PMID:
2543762
41.

Herpes simplex virus type 1 penetration initiates mobilization of cell surface proteins.

Rosenthal KS, Roess D, Barisas BG.

Biochim Biophys Acta. 1988 Jul 7;942(1):38-44.

PMID:
2838084
42.

Enhancement of the antiviral and interferon-inducing activities of poly r(A-U) by carminic acid.

Jamison JM, Flowers DG, Jamison E, Kitareewan S, Krabill K, Rosenthal KS, Tsai C.

Life Sci. 1988;42(15):1477-83.

PMID:
2451107
43.

Flow cytometric evaluation of anti-herpes drugs.

Rosenthal KS, Hodnichak CM, Summers JL.

Cytometry. 1987 Jul;8(4):392-5.

44.

2-deoxy-D-glucose inhibition of herpes simplex virus type-1 receptor expression.

Mohanty JG, Rosenthal KS.

Antiviral Res. 1986 May;6(3):137-49.

PMID:
3015018
45.

Inhibition of herpes simplex virus type 1 penetration by cytochalasins B and D.

Rosenthal KS, Perez R, Hodnichak C.

J Gen Virol. 1985 Jul;66 ( Pt 7):1601-5.

PMID:
2991432
46.

A micropreparation of fluorescein conjugates of immunoglobulin G and Fab from serum.

Mohanty JG, Rosenthal KS.

Anal Biochem. 1985 May 1;146(2):361-5.

PMID:
3927771
47.

Visualization of herpes simplex virus type 1 attachment to target cells using Staphylococcus aureus as a morphologic tag.

Hodnichak CM, Turley-Shoger E, Mohanty JG, Rosenthal KS.

J Virol Methods. 1984 May;8(3):191-8.

PMID:
6086689
48.

Herpes simplex virus binding and entry modulate cell surface protein mobility.

Rosenthal KS, Leuther MD, Barisas BG.

J Virol. 1984 Mar;49(3):980-3.

49.

Cell membrane potential changes follow Epstein-Barr virus binding.

Rosenthal KS, Shapiro HM.

J Cell Physiol. 1983 Oct;117(1):39-42.

PMID:
6311847
50.

Tromantadine: inhibitor of early and late events in herpes simplex virus replication.

Rosenthal KS, Sokol MS, Ingram RL, Subramanian R, Fort RC.

Antimicrob Agents Chemother. 1982 Dec;22(6):1031-6.

Supplemental Content

Loading ...
Support Center